{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:01:51Z","timestamp":1792422111251,"version":"4.5.0"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,5,20]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We evaluated the pattern of chromogranin A (CgA) plasma levels in a large number of patients with neuroendocrine tumors (NETs), in a series of patients with chronic atrophic gastritis (CAG) with and without enterochromaffin-like (ECL) cell hyperplasia, and in healthy participants (HPs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Two hundred thirty-eight patients with NETs, 42 patients with CAG with or without ECL cell hyperplasia, and 48 HPs were studied. All patients underwent a baseline visit, biochemical routine check-up, imaging techniques, endoscopy, and histologic determination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CgA plasma levels were higher in patients with NETs compared with CAG patients or HPs (P &lt; .001). In the NET group, we observed higher CgA levels in patients with diffuse disease compared with patients with local or hepatic disease (P &lt; .001). CgA plasma levels were significantly higher in patients with Zollinger-Ellison syndrome compared with other types of endocrine tumors (P &lt; .001). We found the best cutoff range between HPs and NET patients to be 18 to 19 U\/L (sensitivity, 85.3%; specificity, 95.8%). Comparing all participants without neoplasia (HPs, CAG patients, and disease-free patients) and patients with endocrine tumors, the best cutoff range was 31 to 32 U\/L (sensitivity, 75.3%; specificity, 84.2%). Setting the specificity at 95%, the cutoff range was 84 to 87 U\/L (sensitivity, 55%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study confirms the high specificity and sensitivity of CgA in diagnosing an endocrine tumor. It is necessary to use a cutoff range of 84 to 87 U\/L to obtain a high specificity in diagnosing NETs, with the aim of excluding patients in whom the CgA was elevated as a result of other non-neoplastic diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2006.10.1535","type":"journal-article","created":{"date-parts":[[2007,5,19]],"date-time":"2007-05-19T09:09:49Z","timestamp":1179565789000},"page":"1967-1973","source":"Crossref","is-referenced-by-count":204,"title":["Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?"],"prefix":"10.1200","volume":"25","author":[{"given":"Davide","family":"Campana","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Nori","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidya","family":"Piscitelli","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Maria","family":"Morselli-Labate","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Pezzilli","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Corinaldesi","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tomassetti","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-12-2-181"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198605013141803"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.3109\/02841869109092404"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1007\/BF02067361"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.3109\/02841869309083906"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Nobels FR, Kwekkeboom DJ, Coopmans W, et al: Chromogranin A as serum marker for neuroendocrine neoplasia: Comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82: 2622,1997-2628,","DOI":"10.1210\/jc.82.8.2622"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200101000-00010"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1440049"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1677"},{"key":"R10","unstructured":"Oberg K, Janson ET, Eriksson B: Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol 31: S160,1999-S162,  (suppl 2)"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709000194"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01862"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1480039"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01249.x"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11473"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02030.x"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1770337"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Panzuto F, Severi C, Cannizzaro R, et al: Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 27: 6,2004-11,","DOI":"10.1007\/BF03350903"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1177\/172460080401900407"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi358"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1159\/000096053"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Seregni E, Ferrari L, Bajetta E, et al: Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 12: S69,2001-S72,  (suppl 2)","DOI":"10.1093\/annonc\/12.suppl_2.S69"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1159\/000048842"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-69-4-902"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1500299"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1177\/172460080502000303"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.10.1535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:04:49Z","timestamp":1653494689000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.10.1535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,20]]},"references-count":26,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2007,5,20]]}},"alternative-id":["10.1200\/JCO.2006.10.1535"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.10.1535","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1088806.541907","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,20]]}}}